Replies to post #207631 on Cytodyn Inc (CYDY)

[Neophius]

Hmm, what's at the bottom of that report...hmm...

"The study authors did state that the results needed to be confirmed in a larger, more definitive study. Also noted in the release, is that the study was funded by Leronlimab maker CytoDyn Inc. and conducted by researchers either employed by or serving as consultants to the company."

[misiu143]

LABZ , and yes , the information from leronlimab phase 2 in LH , is so important for a patients well being , that here one more article...

https://www.news-medical.net/news/20220426/The-impact-of-leronlimab-on-CCR5-surface-cell-levels-during-long-COVID.aspx

But I see so many posts , with questions about this study....

Questions like...

1--" Everyone in a trial has some interest in the study.."
2--"CYDY mislead investors with long covid trial report "
3--" but it is ONLY 55 patients "

So I will try to answer some of these questions..

1-2----This publication is a PEER-REVIEWED publication ....as to point 1 and 2..
.
What that mean..??
from the internet description...

" A peer-reviewed publication is also sometimes referred to as a scholarly publication.The peer-review process subjects an author's scholarly work , research , or ideas to the SCRUTINY OF OTHERS WHO ARE EXPERTS in the same field (peers) and is considered necessary to ensure academic quality "

Peer-review takes many , many months to finish..

These are a very high quality results , no one question them in academia .. ...we may need a bigger trial to confirm the results.if needed , but no questions about these results !!! They are shocking really ...

I believe that Pfizer and Moderna vaccination didn't go with peer-review ... why they didn't is another thing , maybe one day we will know...

3----" But only 55 patients .."

55 patients is not a very low number for our FDA if they want it....

About 3 years ago they approved ibalizumab for combo HIV with every 2 weeks IV infusion , with some serious side effects , and only 42% efficacy , and ONLY 40 patients in phase 3 ..before approval..

So it is not how many patients is in the study , but at what point if ever FDA want to approve it .

During last CC DR Kelly said that to do phase 3 in LH , they looking for a partner...looking at the results from phase 2 , partner should come very soon is my opinion...

B52T38..
And talking about transverse myelitis , I believe leronlimab has a good chance.

GLTA longs.

And ALL imo.